skip to main content

H.R. 3: Elijah E. Cummings Lower Drug Costs Now Act

Call or Write Congress

React to this bill with an emoji

Save your opinion on this bill on a six-point scale from strongly oppose to strongly support

Add Note All Positions »
(About Ads | Hide These Ads)

To establish a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees, and for other purposes.

The bill’s titles are written by its sponsor.

Sponsor and status

Photo of sponsor Frank Pallone Jr.

Frank Pallone Jr.

Sponsor. Representative for New Jersey's 6th congressional district. Democrat.

Thumbnail of bill text
Read Text »
Last Updated: Dec 12, 2019
Length: 320 pages
Introduced
Sep 19, 2019
Status

Passed House (Senate next) on Dec 12, 2019

This bill passed in the House on December 12, 2019 and goes to the Senate next for consideration.

Prognosis
65% chance of being enacted according to Skopos Labs (details)
Source
Congress.gov

Position statements

What legislators are saying

“Rep. Chu Response to State of the Union”
    — Rep. Judy Chu [D-CA27] (Co-sponsor) on Feb 5, 2020

“Congressman Dan Kildee Applauds Committee Passage of Bipartisan Surprise Billing Legislation”
    — Rep. Daniel Kildee [D-MI5] (Co-sponsor) on Feb 13, 2020

“Kaptur Statement on the State of the Union Address”
    — Rep. Marcy Kaptur [D-OH9] on Feb 4, 2020

More statements at ProPublica Represent...

What stakeholders are saying

Institute for Spending Reform SpendingTracker.org estimates H.R. 3 will add $40.3 billion in new spending through 2029.
Lymphatic Education & Research Network (LE&RN) The Lymphatic Education & Research Network (LE&RN) is pleased that the Lymphedema Treatment Act (H.R. 1948) will be included in H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act of 2019. The Lymphedema Treatment Act is sponsored by Congressperson ...

History

Sep 19, 2019
 
Introduced

Bills and resolutions are referred to committees which debate the bill before possibly sending it on to the whole chamber.

Read Text »

Sep 25, 2019
 
Considered by Health

A committee held a hearing or business meeting about the bill.

Oct 17, 2019
 
Ordered Reported

A committee has voted to issue a report to the full chamber recommending that the bill be considered further. Only about 1 in 4 bills are reported out of committee.

Read Updated Text » See Changes »

Oct 22, 2019
 
Considered by House Committee on Ways and Means

A committee held a hearing or business meeting about the bill.

Dec 12, 2019
 
Passed House (Senate next)

The bill was passed in a vote in the House. It goes to the Senate next.

thumbnail image of vote View Vote » Read Updated Text » See Changes »

Jan 29, 2020
 
Considered by House Committee on Homeland Security

A committee held a hearing or business meeting about the bill.

If this bill has further action, the following steps may occur next:
—
 
Passed Senate

—
 
Signed by the President

H.R. 3 is a bill in the United States Congress.

A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.

How to cite this information.

We recommend the following MLA-formatted citation when using the information you see here in academic work:

“H.R. 3 — 116th Congress: Elijah E. Cummings Lower Drug Costs Now Act.” www.GovTrack.us. 2019. February 16, 2020 <https://www.govtrack.us/congress/bills/116/hr3>

Where is this information from?

GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.